

A.45	Ticagrelor – prevention of atherothrombotic events – EML
Draft recommendation	<input type="checkbox"/> Recommended <input checked="" type="checkbox"/> Not recommended <p>Justification: potent inhibitors of P2Y₁₂ enzyme including ticagrelor and prasugrel along with clopidogrel with similar efficacy profiles could be administered for prevention of atherothrombotic events. Published data regarding comparative cost effectiveness of ticagrelor in different health care systems are not yet conclusive. Possible risk of bleeding in high risk patients who received ticagrelor also is a concern.</p> <p>Due to comparative safety and efficacy of commonly available anti platelet medicines on the market, It is proposed that the section of anti-platelet medicines to be reviewed for the next meeting (2025)</p>
Does the proposed medicine address a relevant public health need?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable Comments:
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? <small>(this may be evidence included in the application, and/or additional evidence identified during the review process)</small>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable Comments:
Does adequate evidence exist for the safety/harms associated with the proposed medicine? <small>(this may be evidence included in the application, and/or additional evidence identified during the review process)</small>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable Comments:
Are there any adverse effects of concern, or that may require special monitoring?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable Comments: Possibility of bleeding in high risk patients

24th WHO Expert Committee on Selection and Use of Essential Medicines
Expert review

<p>Are there any special requirements for the safe, effective and appropriate use of the medicines?</p> <p>(e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?</p>	<p><input checked="" type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments: Published data regarding comparative cost effectiveness of Ticagrelor in different health care systems are not yet conclusive.</p>
<p>Are there any issues regarding the registration of the medicine by national regulatory authorities?</p> <p>(e.g. accelerated approval, lack of regulatory approval, off-label indication)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Is the proposed medicine recommended for use in a current WHO guideline?</p> <p>(refer to: https://www.who.int/publications/who-guidelines)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>